Indaptus Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized**.**
| Indaptus Therapeutics, Inc. | ||
| Date: March 13, 2025 | By: | /s/ Jeffrey A. Meckler |
|---|---|---|
| Jeffrey A. Meckler | ||
| Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jeffrey Meckler and Nir Sassi, and each of them acting individually, as his attorney-in-fact, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorney to any and all amendments to said Report.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Jeffrey A. Meckler | Chief Executive Officer and Director | March 13, 2025 |
| Jeffrey A. Meckler | (Principal Executive Officer) | |
| /s/ Nir Sassi | Chief Financial Officer | March 13, 2025 |
| Nir Sassi | (Principal Financial and Accounting Officer) | |
| /s/ Michal J. Newman, Ph.D. | Chief Scientific Officer and Director | March 13, 2025 |
| Michael J. Newman, Ph.D. | ||
| /s/ Roger J. Pomerantz, M.D. | Chairman of the Board of Directors | March 13, 2025 |
| Dr. Roger J. Pomerantz, M.D. | ||
| /s/ Hila Karah | Director | March 13, 2025 |
| Hila Karah | ||
| /s/ Anthony J. Maddaluna | Director | March 13, 2025 |
| Anthony J. Maddaluna | ||
| /s/ Mark J. Gilbert | Director | March 13, 2025 |
| Mark J. Gilbert | ||
| /s/ William B. Hayes | Director | March 13, 2025 |
| William B. Hayes | ||
| /s/ Robert E. Martell, M.D., Ph.D. | Director | March 13, 2025 |
| Robert E. Martell, M.D., Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.